Gubra A/s · OMXCOP:GUBRA
Gubra A/s — Q1 2023 Earnings Presentation
15 slides from Gubra A/s's earnings presentation, May 11, 2023
Slide 1: Q1-2023 investor presentation
Q1-2023 TRADING STATEMENT Share ticker: Gubra NASDAQ Copenhagen Q1-2023 investor presentation 11 May 2023 Present from Gubra: Henrik Blou, CEO Niels Vrang, CSO Kristian Borbos, CFO Investor conference call 11 May 2023, 10:00am CET Follow live via: https://events.q4inc.com/attendee/322801355/guest Di
Slide 2: Forward looking statements
Forward looking statements Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe“, “expect“, “anticipate“, “intends“, “estimate“, “will“, “may“, “c
Slide 3: Q1-2023 – Good start to the year
Q1-2023 – Good start to the year IPO completed • Provides foundation for accelerated growth • High-quality investors in the IPO CRO business: • Strong revenue growth: 19% y/y • Solid earnings: 29% EBIT-margin D&P business: • Expansion of streaMLine platform to handle cyclic peptides • Amylin peptide
Slide 4: The Gubra Hybrid Business Model
The Gubra Hybrid Business Model CRO Services Discovery & Partnerships Specialized pre-clinical Discovery, design and contract research and development of peptide- development services based drug candidates for the pharmaceutical with the aim of entering and biotechnology partnerships with industry.
Slide 5: Gubra operates in the early stage of the value chain
Gubra operates in the early stage of the value chain PHARMA/BIOTECH VALUE CHAIN AND GUBRA’S FOCUS AREA Discovery Clinical Development Pre-clinical Target ID & validation Hit/lead generation Lead optimization Phase I Phase II Phase III Approval & sales development Gubra’s value chain focus Latest par
Slide 6: IPO providing foundation for accelerated growth
IPO providing foundation for accelerated growth M&A ACTIVITIES LIQUIDITY CRO SALES – ~50%(1) GEOGRAPHIC EXPANSION CONTINUED ~10%(1) DEVELOPMENT OF THE COMPANY’S TECH PLATFORM VISIBILITY CONTINUED ~10%(1) DEVELOPMENT OF THE COMPANY'S EXISTING PIPELINE ~30%(1) RECRUITMENT GUBRA GUBRA TODAY FUTURE Note
Slide 7: Our CRO business
CRO business OVERVIEW OF GUBRA’S DISEASE AREAS AND SERVICE OFFERING Our CRO business 3D Imaging Diabetes Liver Lungs Heart • Specialised in the pre-clinical phase with a (NASH) (CVD) stronghold in metabolic and fibrotic diseases • Highly ranked translatable rodent models 2D Histology • End-to-end di
Slide 8: CRO business: Q1-2023 in summary
CRO business Revenue DKKm 19% 38.7 Q1-2023 in summary 32.5 • Revenue up 19% y/y • Growth across different disease areas • Especially strong growth within: Q1-2022 Q1-2023 • NASH – supported by industry late-stage clinical data in H2-2022 → positively affecting demand for Gubra’s preclinical NASH mod
Slide 9: The streaMLine platform for drug discovery
D&P business The streaMLine platform for drug discovery Our Discovery & Partnership business (D&P) • Discovery, design and development of peptide-based drug candidates • Through our streaMLine platform we can: • Accelerate clinical candidate identification • Enhance potential for stronger patent pro
Slide 10: Gubra's R&D Pipeline
Gubra’s R&D Pipeline Healthy mix of internal & partnered programs 10
Slide 11: D&P business: Q1-2023 in summary
D&P business Total adjusted costs Revenue excl. Amylin* DKKm DKKm Q1-2023 in summary 85-95 18.2 • streaMLine platform expanded to also handle cyclic 20.7 11.2 peptide drug candidates 16.2 • Progress also made to handle even more complex peptides such as macrocyclic peptides Q1- Q1- FY-2023 Q1- Q1- 2
Slide 12: Gubra Green
Gubra Green Nature Positive and Carbon Negative Gubra Green GUBRA GREEN • We are investing 10% of pretax profit from Gubra A/S into Gubra Green on green initiatives 90% OF RETURNS PASSIVE INVESTMENTS ONLY generated in Gubra Green will be to ensure that limited resources • Gubra Green is a fully owne
Slide 13: Financial outlook and guidance
Financial outlook and guidance FY-2023 Mid-term Results outlook guidance Q1-2023 CRO Segment Organic revenue growth 10% 10% annually 19% EBIT-margin excl. special items ~25% 35-40% 29% Discovery & Partnership Segment Number of new partnerships 1-2 1-2 – Total costs (cost of sales and operating costs
Slide 14: Concluding remarks – our strategic priorities
Concluding remarks – our strategic priorities OUR STRATEGIC PRIORITIES CRO – Develop the business and drive top line growth and profitability through: • Further expand the catalogue for speciality and translatable animal models • Continued focus on automation and digitalisation • Establishment of US
Slide 15: Thank you for your attention!
Thank you for your attention! Gubra A/S Hørsholm Kongevej 11B DK-2970 Hørsholm Denmark www.gubra.dk Let’s stay connected Gubra presentation 15